severe cutaneous adverse reaction

severe cutaneous adverse reaction

,

SCAR.

Any of several potentially life-threatening rashes resulting from exposure to a drug. Included in this group are acute generalized exanthematous pustulosis, drug reactions with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
References in periodicals archive ?
Allopurinol was found to be leading cause of severe cutaneous adverse reaction.
Usage of allopurinol should be with clear indication due to high risk of severe cutaneous adverse reaction.
The secondary outcome was in-hospital death during that hospitalization for severe cutaneous adverse reaction.
In the crude analysis, age, comorbidity index score, and any use of diuretics were significantly associated with a severe cutaneous adverse reaction.
Severe cutaneous adverse reaction was the most common reported single-organ dysfunction.
Based on European Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) study group, scoring of more than or equal to four (hospitalization, acute onset exanthema with fever, involvement of at least one internal organ), the patient was diagnosed to have DRESS syndrome.
This has been reported in Severe Cutaneous Adverse Reactions (SCAR), especially Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and is attributed to the immune activation induced by a severe drug reaction, which predisposes the patient to manifest hypersensitivity to otherwise well tolerated drugs.
Stevens-Johnson syndrome involves rare but severe cutaneous adverse reactions related to a variety of medications including antibiotics (6).
The pharmacogenomics of severe cutaneous adverse reactions to allopurinol have been recently elucidated in the Han Chinese.
reported on 281 patients with Stevens-Johnson syndrome (SJS) or toxic epidermal necrosis (TEN) treated in French and German hospitals under the auspices of the European Registry of Severe Cutaneous Adverse Reactions (EuroSCAR) study group.
AEDs have been recognized as being among the most common medications associated with severe cutaneous adverse reactions, with relative risks reported to be 15%, 11%, 13%, and less than 5% for phenobarbital, CBZ, PHT, and oxcarbazepine, respectively.
These severe cutaneous adverse reactions (SCAR) are characterized by epidermal necrosis, extensive detachment of the epidermis, erosions of the mucous membranes and severe constitutional symptoms.
Full browser ?